TP53 and osteosarcoma: To assess whether pre-treatment with an Mdm2 inhibitor affects the survival of p53-proficient cells, we first treated U2OS cells (human osteosarcoma, p53 wild type) with Nutlin-3a, the prototype pharmacological antagonist that binds to Mdm2 and precludes its interaction with p53 [17].